Needham cuts Hims and Hers stock price target on weak results
Needham reduced its price target for Hims and Hers Health (NYSE:HIMS) to $32 from $42, citing weak Q3 results. Revenue and adjusted EBITDA missed expectations, and subscriber count declined. The company lowered guidance but maintains a Buy rating. HIMS shares fell 10.74% last week, trading at $22.94. The company plans to cut marketing spend and expand internationally.
How this was made
The 30-second read
Why it matters
Analyst downgrade and weaker guidance are likely to drive the stock lower in the near term, while the company's international expansion plans may provide future upside.
Market read
The fresh analyst downgrade and guidance cut constitute material new information for HIMS, creating a clear short‑term trading signal.
What to watch
Potential upside from upcoming international expansion and weight‑loss product pipeline could mitigate short‑term weakness.
Background
Hims & Hers Health reported Q3 2026 results with revenue up 49% YoY but missed profit expectations and lowered guidance, prompting an analyst target cut.
Ticker impact
Needham cut Hims & Hers price target to $32 from $42 after weak Q3 results and lowered guidance.
downward pressure as investors price in weaker guidance and lower target.
Analyst target cut and below‑consensus results are fresh, material information for a mid‑cap stock.
Market effects
Telehealth and digital health peers may face heightened scrutiny on guidance and marketing spend.
U.S. small‑cap health tech segment could see modest pullback.
Limited; impact confined to U.S. listed health‑tech equities.
Counterpoint
Some investors may view the price dip as a buying opportunity if they believe the long‑term growth narrative remains intact.
Key entities
- analystNeedham
Equity research firm that lowered the price target for HIMS.
- companyHims & Hers Health
Telehealth provider reporting Q3 results and guidance.
